Literature DB >> 7572759

Chemotherapy for Merkel cell carcinoma with carboplatin and etoposide.

D Pectasides1, G Moutzourides, M Dimitriadis, J Varthalitis, A Athanassiou.   

Abstract

Merkel cell carcinoma is a rare malignant tumor of the skin. We treated three patients with Merkel call carcinoma with the combination of carboplatin and etoposide, which have been mostly used in the treatment of small cell lung carcinoma. Two patients experienced partial remission of short duration. The third patient received the combination on an adjuvant basis but relapse occurred briefly. Two of these patients failed to respond to second-line chemotherapy with cisplatin, ifosfamide, and epirubicin. The patient who had the first-line treatment on an adjuvant basis, responded completely with the second-line chemotherapy plus radiotherapy and remains disease-free for 5+months. Merkel cell carcinoma appears to be a sensitive tumor to chemotherapeutic regimens used for small cell lung carcinoma, but the responses are often brief.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572759     DOI: 10.1097/00000421-199510000-00011

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

Review 1.  [Primary radiotherapy of recurrent Merkel cell carcinoma of the eyelid. Case report and review of the literature].

Authors:  S Höcht; T Wiegel
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

2.  Surgical management of Merkel cell carcinoma.

Authors:  P J Allen; Z F Zhang; D G Coit
Journal:  Ann Surg       Date:  1999-01       Impact factor: 12.969

3.  Prognostic Value of Radiotherapy and Chemotherapy in Stage I-III Merkel Cell Carcinoma.

Authors:  Aihong Bi; Sifu Yang; Yang Ding; Yong Yu; Wenming Zhan; Tao Song
Journal:  Front Med (Lausanne)       Date:  2022-02-18

Review 4.  Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment.

Authors:  Urs Dietmar Achim Müller-Richter; Anja Gesierich; Alexander Christian Kübler; Stefan Hartmann; Roman Camillus Brands
Journal:  Ann Surg Oncol       Date:  2017-07-31       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.